ecancermedicalscience

Special Issue

Neoadjuvant immunotherapy in breast cancer: a paradigm shift?

3 Dec 2020
Elena Fountzila, Michail Ignatiadis

Despite advances in clinical management, a proportion of patients with early-stage triple-negative breast cancer (TNBC) recur after local treatment. The concept of neoadjuvant systemic therapy has been widely adopted to improve clinical outcomes of patients with TNBC and other breast tumour types. Recently, promising data were reported from the first prospective phase III, randomised trial assessing neoadjuvant chemotherapy combined with the programmed cell death protein 1 (PD-1) inhibitor pembrolizumab versus placebo in patients with early-stage TNBC. The addition of pembrolizumab resulted in a significant increase in pathologic complete response (pCR) rates. Similarly, in the IMpassion031 trial, the use of atezolizumab in combination with neoadjuvant chemotherapy in patients with early-stage TNBC led to improved pCR rates compared to placebo, regardless of programmed death ligand 1 (PD-L1) expression. Ongoing trials are testing other PD-1/PD-L1 inhibitors in combination with neoadjuvant chemotherapy in TNBC and other tumour subtypes. However, not all patients benefit from the addition of immunotherapy, while a proportion of patients experiences serious adverse events. It is critical to identify predictive biomarkers of response, to accurately select patients who will benefit from immunotherapy, thus sparing the rest from ineffective treatments with unnecessary toxicity and treatment costs. In this review, we summarise the literature on reported and ongoing neoadjuvant clinical trials evaluating immunotherapy in breast cancer.

Related Articles

Bolanle C Adegboyega, Adewumi O Alabi, Adedayo O Joseph, Nwamaka Lasebikan, Luther A Agaga, Kehinde O Ololade, Anthonia C Sowunmi
Shridevi Subramaniam, Yek-Ching Kong, Hafizah Zaharah, Cuno SPM Uiterwaal, Andrea Richard, Nur Aishah Taib, Azura Deniel, Kok-Han Chee, Ros Suzanna Bustamam, Mee-Hoong See, Alan Fong, Cheng-Har Yip, Nirmala Bhoo-Pathy
Tapesh Bhattacharyya, Moses Arunsingh, Santam Chakraborty, Vishnu Harilal, Rohit Sasidharan, Saheli Saha, Robin Thambudorai, Bipradas Roy, Sudeep Banerjee, Paromita Roy, Soumendranath Ray, Indranil Mallick
Marianne Gnanamuttupulle, Oliver Henke, Shilanaiman Hilary Ntundu, Furaha Serventi, Leila E Mwakipunda, Patrick Amsi, Alex Mremi, Kondo Chilonga, David Msuya, Samuel G Chugulu
Prisca O Adejumo, Toyin IG Aniagwu, Olutosin A Awolude, Abiodun O Oni, Olubunmi O Ajayi, Omolara Fagbenle, Dasola Ogungbade, Makayla Kochheiser, Temidayo Ogundiran, Olufunmilayo I Olopade
Laudy Chehade, Jad Zeitoun, Rachelle Bejjany, Maya Charafeddine, Firas Kreidieh, Mona Hassan, Ali Taher, Nagi El Saghir, Ali Shamseddine, Ziad Salem, Sally Temraz, Arafat Tfayli, Hazem Assi, Ali Bazarbachi, Jean El Cheikh, Iman Abou Dalle, Nesrine Rizk, Rami Mahfouz, Deborah Mukherji